Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based compensation arrangements, options, grants in period, weighted average exercise price	$ 5.36	$ 8.50
Share-based compensation aggregate fair value of option	$ 1,500	$ 500
Weighted-average grant date fair value of options vested		$ 9.00
Aggregate fair value of restricted stock units	400	$ 200
Total unrecognized compensation cost related to unvested stock options and restricted stock units	2,500
Employee Stock Purchase Plan [Member]
Share-based compensation expense	$ 40
Stock Incentive Plan [Member]
Share-based compensation arrangement by share-based payment award, description	Stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units ("RSUs") granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.